Video
Jelmyto for low-grade UTUC: Clinical experience and side effects to watch for
Author(s):
Angela B. Smith, MD, MS, describes her institution’s early clinical experience with mitomycin-containing reverse thermal gel (Jelmyto).
Video Player is loading.
In this video, Angela B. Smith, MD, MS, also outlines side effects of Jelmyto that urologists should watch for. Smith is vice chair of academic affairs, director of urologic oncology, and associate professor of urology at UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
Related Videos
5 key trial insights from AUA 2025
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
Related Content
